Cytosorbents Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Cytosorbents Corporation (CTSO) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-20.72-28.51-32.81-24.56-7.84-19.27-17.21
Depreciation & Amortization1.752.021.131.130.980.700.39
Stock Based Compensation3.764.163.806.204.710.000.00
Change in Working Capital-4.382.65-3.560.64-0.76-1.45-0.94
Change in Accounts Receivable-1.72-0.25-1.290.42-0.330.000.00
Change in Inventory0.500.180.95-2.35-0.460.000.00
Change in Accounts Payable-1.811.61-3.252.431.110.000.00
Change in Other Working Capital-1.350.040.030.15-1.080.000.00
Other Operating Activities5.160.042.456.204.612.910.73
Net Cash from Operating Activities-14.43-21.66-28.23-14.01-5.61-16.76-10.84
Investing Activities
Capital Expenditures-0.28-0.94-6.464.281.681.52-0.67
Sales/Maturities of Investments0.00-0.40-0.37-0.64-0.970.000.00
Other Investing Activities-0.390.000.000.000.000.000.00
Net Cash from Investing Activities-0.67-0.94-6.46-4.28-1.68-1.52-1.52
Financing Activities
Debt Repayment10.000.000.000.00-16.410.00-0.67
Common Stock Issued0.1814.260.000.8181.720.0014.13
Common Stock Repurchased0.000.00-0.04-0.090.000.000.00
Other Financing Activities-0.8514.26-0.04-0.0979.840.67-0.15
Net Cash from Financing Activities9.3314.474.960.7266.358.1817.47
Summary
Effect of Forex Changes on Cash-0.08-0.10-0.26-0.020.13-0.04-0.06
Net Change in Cash-5.85-8.12-29.73-17.5759.19-10.145.11
Cash at Beginning of Period15.6223.8353.8371.4212.2322.3717.32
Cash at End of Period9.7615.6223.8353.8371.4212.2322.37
Free Cash Flow-14.71-22.59-34.69-18.29-7.29-18.28-12.36
Supplemental Disclosures
Interest Paid1.290.380.000.001.131.060.89